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Background & Aims: Ischemia-reperfusion (IR) of liver results in hepatocytes (HP) and sinusoidal 
endothelial cells (LSEC) irreversible damage. Ischemic preconditioning protects IR damage upon 
adenosine A2a receptor (A2aR) stimulation. Understanding the phenotypic changes that underlie 
hepatocellular damage and protection is critical to optimize strategies against IR.  
Methods: The proteome of HP and LSEC isolated from sham or IR exposed mice receiving or  
not the A2aR agonist CGS21680 (0.5 mg/kg b.w.) was analyzed by 2-D DIGE/MALDI-TOF.  
Results: we identified 64 proteins involved in cytoprotection, regeneration, energy metabolism and 
response to oxidative stress; among them 34  were never reported associated to IR injury and A2aR 
protection. The main pathways down-regulated by IR and up- regulated by CGS21680 in HP and 
LSEC, were related to carbohydrate, protein and lipid supply and metabolism. In LSEC, IR reduced 
stress response enzymes, that were instead up-regulated by CGS21680 treatment. Functional 
validation experiments confirmed the metabolic involvement and showed that the inhibition of 
pyruvate kinase, 3-chetoacylCoA thiolase and arginase reduced the protection given by CGS21680 
of in vitro hypoxia- reoxigenation injury, whereas their metabolic products induced liver cells 
protection. Moreover, LSEC, but not HP, were sensitive to H2O2-induced oxidative damage and 
CGS21680 protected against this effect. 
Conclusions: IR and A2aR stimulation produces pathological and protected liver cells phenotypes 
respectively characterized by down- and up- regulation of proteins involved in the response to O2 
and nutrients deprivation during ischemia, oxidative stress and reactivation of aerobic energy 
synthesis at reperfusion. This provides novel insides in IR hepatocellular damage and protection and 



































































Inflow occlusion during liver surgery with consequent reperfusion causes liver ischemia-reperfusion 
(IR) injury. IR causes up of 10% early graft dysfunction or failure during liver transplantation (1). 
IR injury is the result of a complex series of alterations that mainly involve hepatocytes (HP) and 
sinusoidal endothelial cells (LSEC) (2). Several events contribute to liver damage by IR. The lack 







 homeostasis with alteration of the volume regulatory mechanisms and 
eventually necrosis. Upon oxygen re-admission, the uncoupled mitochondria generate reactive 
oxygen species (ROS) with oxidative stress, mitochondrial permeability transition and decreased 
capacity to synthesize ATP.  These events along with caspase activation lead to cell death by both 
necrosis and apoptosis. Concomitantly, activation of the inflammatory reactions is also associated to 
the onset of IR (3,4). Minimizing the adverse effects of IR could significantly increase the number 
of transplantable organs and improve the outcome of the grafts (5).  
Preconditioning is a powerful protective phenomenon able to activate endogenous systems that 
make tissues resistant to a subsequent lethal stress (6). Liver ischemic preconditioning, defined as 
brief periods of ischemia and reperfusion before sustained hepatic ischemia, can preserve energy 
loss, reduce transaminases release, inhibit inflammatory reactions and promote liver regeneration 
after IR injury (4,7). The surgical application of ischemic preconditioning represents a promising 
approach to protect against hepatic IR in humans.  Its use, however, has the main disadvantage of 
inducing trauma to major vessels and stress to the target organ (8) and clinical studies have given 
conflicting results  that have prevented the clinical use of ischemic preconditioning (4,8,9).  These 
observations indicated the necessity to explore alternative approaches to activate ischemic 
preconditioning in patients. To this respect, pharmacological induction of liver preconditioning 
could represent a more efficient and reliable technique. Studies in vitro and in vivo have established 
a key role of the adenosine A2a receptor (A2aR) stimulation as an approach for pharmacological 
induction of liver preconditioning (4,10-12). Even short periods of hypoxia, in fact, lead to the 


































































ATP. Accumulation of adenosine protects tissues from injury upon signalling through the adenosine 
receptor A2aR (4,12). Expression of new synthesized proteins can also contribute to the production 
of the protected liver cell phenotypes (13). The changes of protein expression of preconditioned as 
well as IR injured HP and LSEC are, up to now, poorly characterized. The present work analysed 
the proteomic patterns of primary HP and LSEC isolated from mouse liver following IR with or 
without pre-treatment with the A2aR agonist CGS21680 to identify new targets for the development 





Chemicals and reagents 
Protease inhibitors, nuclease, ammonium persulfate (APS), bromophenol blue, glycerol, 
N,N,N9,N9-tetramethylethylene-diamine (TEMED), sodium dodecyl sulfate (SDS), TRIZMA, urea, 
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate (CHAPS), dithiothreitol (DTT), 
iodoacetamide, Dulbecco’s modified Eagle medium culture medium  (DMEM), Trypan Blue, 2p-(2-
carboxyethyl)-phenyl-amino-5-N-ethylcarboxya-mido-adenosine (CGS21680), Palmitic Acid, Non 
essential amino acid  mixture (AA, 100X), Suramine (SUR), Norvaline (NRV), Piruvate,  
Trimetazidine (TMZ), 2,7-dichlorofluorescin diacetate (DCFH-DA), BCA kit, Enzymatic Assay of 
Pyruvate Kinase Kit and ATP Bioluminescent Assay Kit were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). DC Protein assay kit, acrylamide, agarose, ready-made immobilized pH gradient 
(IPG)strip (17-cm IPG strips, pH 3-10NL) were purchased from Bio-Rad (Hercules, CA, USA). 
Ampholine pH 3.5–10, western blot detection system, membranes for blotting, antirabbit and 
antimouse IgG horseradish-peroxidase-labeled antibodies were obtained from GE Healthcare (MI, 
ITALY). Rabbit antibody against arginase 1 was purchased from Thermo Scientific (Illkirch Cedex, 


































































CA, USA). TaqMan Gene Expression Master Mix and Taqman Gene Expression probes for mouse 
3-ketoacyl-CoA thiolase, arginase 1, -enolase and β-actin or 18S were from Applied Biosystems 
Italia (Monza, Italy). 
 Animals  
Male C57BL/6  mice were used for this study purchased at Harlan srl, Italy. All animal experiments 
were approved by the Italian Ministry of Health and by the Università del Piemonte Orientale ―A. 
Avogadro‖ Ethical Committee for Animal Care. 
Ischemia-reperfusion injury 
Mice were exposed for 30 min to a non lethal (-70% of the total liver volume) hepatic ischemia 
followed by 120 reperfusion as previously described (14). Pharmacological A2aR activation was 
induced by i.p. injection of CGS21680  (0.5 mg/kg of body weight) 20 min before the ischemia. 
Liver injury was assessed by measuring the ALT serum transaminase activity by a commercial kit 
(Gesan Production, ITALY) and the morphological alterations by histological observation . Details 
are provided in the Supporting Information. 
Liver cells isolation and treatment 
Liver cells were isolated by liver perfusion with collagenase digestion from sham operated mice or 
mice exposed to IR pretreated or not with CGS21680. HP were obtained by differential 
centrifugation at 50xg for 5 min at 4°C and LSEC by immunomagnetic separation using a negative 
selection with a mouse anti-CD45 and positive selection with anti-CD146 antibodies linked to 
immunomagnetic beads (Miltenyibiotec, Calderana di Reno, BO, ITALY)  as previously reported 
(15) and described in details in the Supporting Information. 
Isolated HP and LSEC for proteomic analysis were stored at -80°C until solubilization. 
For evaluation of hypoxia-reoxygenation injury, primary HP and LSEC  were resuspended (10
6
/mL 
cell density) in Viaspan solution (University of Wisconsin solution without additives) and fluxed 
with 95% N2/5% CO2  and maintained at 4°C for 16 hours in sealed flasks. For reoxygenation, 


































































hydroxyethyl)-piperazine-N0-(2-ethanesulfonic acid) (pH 7.4 at 37°C), and the incubation flasks 
were further fluxed with a 95% air/5% CO2 gas mixture. When indicated, liver cells, suspended in 
the Viaspan solution, were pre-incubated 15 min at 37° C before cold preservation with CGS21680 
(5 mol/l) and/or suramine (SUR, 20 mol/l), norvaline (NRV, 50 mol/l), trimetazidine (TMZ, 
100 mol/l),  pyruvate (10 mol/l), palmitic acid (PA,2 mol/l) or non-essential amino acid  
mixture (AA, 10%).  To evaluate oxidative damage, HP or  LSEC in Krebs-Henseleit buffer, were 
treated with H2O2 (500 mol/l) in presence or in absence of CGS21680 (5 mol/l) and incubated 
for 30 min at 37°C under  a 95% air/5% CO2 gas  atmosphere.   
Determination of Cell Viability 
Cell viability was estimated by the determination of nuclear fluorescence staining with propidium 
iodide using a FACScan analyzer (Becton-Dickinson, San Jose, CA) and CellQuest software 
(Becton-Dickinson) (13). 
Measurement of Reactive Oxygen Species (ROS) 
Intracellular ROS production was measured as reported in (14) by measuring the DCFH-DA (2,7-
dichlorofluorescin diacetate) fluorescence intensity with a Hitachi F-4500 fluorescence 
spectrophotometer. Details are provided in the Supporting Information. 
 Data Analysis 
Statistical analysis was performed with InStat 3 statistical software (GraphPad Software, Inc., San 
Diego, CA) by 1-way analysis of variance testing with Bonferroni correction for multiple 
comparisons when more than 2 groups were analyzed. The distribution normality of all groups was 
preliminarily verified with the Kolmogorov and Smirnov test. Significance was established at the 
5% level. 
Proteomic analysis 
Two-dimensional gel electrophoresis (2-DE) on ready-made IPG strip (17-cm IPG strips, pH 3-
10NL) were performed essentially as described (16). For 2-D DIGE analysis fifty micrograms of 


































































DIGE Fluors following the manufacturer’s instruction (GE Healthcare). For 2DE coomassie stained 
gel, 1 mg of total liver protein was loaded. Destaining and in-gel enzymatic digestion of G-stained 
spots were performed as previously described (16). All digests were analyzed by MALDI-TOF 
(TofSpec SE, MicroMass). Details are provided in the Supporting Information. 
To verify the significance of the proteins expression variations two-sided Student’s t test was used. 
Experiments were performed in triplicate. Statistical significance was set at p values≤0.05. Proteins 
were classified as differentially expressed if ratio in spot intensity was greater than 1.5-fold (protein 
over-expressed) or lower than 0.5-fold (protein under-expressed).  
The protein and RNA levels of ketoacyl-CoA thiolase, arginase 1 and -enolase were evaluated by 
western blotting and RT-PCR analysis as described in the Supporting Information.  
Enzymatic assays 
Aldolase B activity was measured as described in (17), with minor modifications. -enolase activity 
was measured accordingly to (18). The activity of pyruvate kinase was detected with the Enzymatic 
Assay of Pyruvate Kinase kit, following the manufacturer’s instruction. Fatty acids β-oxidation was 
measured as previously reported (19), with minor modifications. The activity of carbamoyl 
phosphate synthetase I was measured on mitochondrial extracts, isolated as previously reported 
(20). Arginase activity was measured by a spectrophotometric method (21). To measure the 
isocitrate dehydrogenase activity, 25 µg mitochondrial proteins were re-suspended in 0.3 mL of 
Tris-acetate (pH 7.4), containing 5 mmol/L DL-isocitrate trisodium salt and 5 mmol/L MgCl2. The 
reaction was started by adding 0.5 mmol/L NAD
+
 and the absorbance at 340 nm was followed for 5 
minutes. Results were expressed as nmol NADH/mg mitochondrial proteins. The rate of 
cytochrome c reduction was measured according to (22) with minor modifications. The ATP level 
in mitochondria extracts was measured with the ATP Bioluminescent Assay Kit. Additional details 






































































Analysis of liver injury following IR and A2aR stimulation  
Mice exposure to 30 min of hepatic ischemia followed by 120 min reperfusion caused substantial 
liver injury as determined by the serum ALT (alanine transaminase) release and hepatic histology 
(Supplementary Fig. 1). In accordance to previous observations (4,12), stimulation of adenosine A2 
receptors by mice treatment with CGS21680 (0.5 mg/kg b.w.) before IR significantly reduced the 
serum ALT increase and markedly attenuated the signs of hepatocyte necrosis and sinusoidal 
congestion detected by hematoxylin and eosin staining (Supplementary Fig. 1).  
Proteomic analysis following IR and A2aR stimulation 
2-D DIGE proteomic analysis was performed to elucidate the phenotypic changes of HP and LSEC 
isolated from mice livers exposed to IR with or without A2aR stimulation (Supplementary Fig.2, 
Supplementary Tables 1,2,3) 
By comparing HP and LSEC of sham operated mice vs mice subjected to IR, we observed that 16 
proteins were down-regulated (Fig. 1, Supplementary Table 1). In particular, in both HP and LSEC, 
IR reduced proteins involved in glycid, lipid and mitochondrial (Krebs cycle and oxidative 
phosphorylation) metabolism. Notably, IR decreased, in LSEC specifically, two proteins related to 
the response to oxidative stress (Fig.1). 
Compared to control, treatment with the A2aR agonist CGS 21680 alone affected the expression of 
metabolic proteins: 6 were up-regulated and 1 was  down-regulated (Fig. 1, Supplementary Table 
2).    
The treatment with CGS21680 and IR vs control, with the exception of three proteins that were 
down-regulated in HP,  up-regulated 10 proteins, mostly metabolic enzymes associated to ATP 
synthesis, glycolysis, lipid and aminoacid catabolism, and cell response to stress (Fig. 1, 


































































proteins down-regulated by IR, with 14 proteins that recovered control level and two that were up-
regulated (Fig. 1, Supplementary Table 3).  
It is noteworthy, that when cell extracts obtained from mice receiving CGS21680 with IR were 
compared to those exposed to IR alone evidenced a more complex and unexpected scenario. We 
found, that further 19 proteins, including metabolic, stress-related  and folding-related proteins, 
were up-regulated (Fig. 1, Supplementary Table 3).   
Also the comparison IR plus CGS21680 vs CGS21680 did not reproduce the protein profile of IR 
alone (Fig. 1, Supplementary Table 1 and 3). We detected the modulation of 41 proteins and, most 
intriguingly, 34 of them were up-regulated whereas in IR vs control all proteins were down-
regulated. Among the up-regulated proteins, we evidenced metabolic and stress related enzymes.       
Altogether, in both HP and LSEC, A2aR stimulation by CGS21680 alone and, even more when 
followed by IR, up-regulated proteins associated to DNA synthesis and cytoprotection. Intriguingly, 
the pathways mainly involved were related to cell response to stress and, more markedly, to the  
carbohydrate, lipid, and amino acids supply and catabolism (Fig. 2).  Thus suggesting a possible 
role of the antioxidant and of the catabolic enzymes in the hepatoprotective effects of A2aR 
stimulation.  
Proteomic data have been validated by western blot and RT-PCR analysis on three key metabolic 
enzymes (ENOA, THIM and ARGI1) (Supplementary Fig. 3). 
Functional validation of the metabolic effect of A2aR stimulation on HP and LSEC 
Proteomic data showed that A2aR stimulation increased the expression of several catabolic 
enzymes, that were instead reduced following IR (Fig.1, Supplementary Table 1,2 and 3). To 
functionally confirm this observation, the activity of several enzymes referred to glycid, lipid, 
aminoacid and mitochondrial metabolism was assayed.  
The activity of glicolytic enzymes -enolase (ENOA) and pyruvate kinase (KPYR) was down-


































































bisphosphate aldolase B (ALDOB) was down-regulated by IR and up-regulated by IR plus 
CGS21680 in HP only (Fig. 3).  
For lipid metabolism, we evaluated the products of  -oxidation reactions, that were down-regulated 
by IR and up regulated by IR plus CGS21680 in HP and LSEC (Fig. 3).  
For aminoacid catabolism, the activity of two enzymes linked to urea cycle, namely carbamoyl-
phosphate synthase (CPSM)  and arginase 1 (ARGI1) was evaluated. The activity of CPSM was 
reduced by IR (although not significantly in LSEC) and strongly up-regulated by IR plus 
CGS21680 (Fig. 3). The activity of ARGI1 was significantly down regulated by IR and up-
regulated by IR plus CGS21680 in HP only. 
For mitochondrial metabolism, the activity of  isocitrate dehydrogenase  (IDHC) and cytochrome C, 
and the ATP production were measured. The activity of IDHC and cytochrome C was significantly 
down-regulated by IR and up-regulated by IR plus CGS21680 in both HP and LSEC, whereas ATP 
production was the same but only in HP (Fig. 3). 
These data clearly indicate that IR strongly reduces the metabolism and that CGS21680 rescues it in 
both HP and LSEC, confirming the observations obtained by proteomic approach.  
Functional validation of the cytoprotective role of metabolic enzymes in A2aR-induced 
resistance to death of HP and LSEC  
To evaluate the cytoprotective meaning of the up-regulation of the metabolic enzymes in HP and 
LSEC obtained from mice treated with CGS21680 before hepatic IR, we applied an in vitro model 
of IR injury using primary HP and LSEC  preserved in hypoxic conditions in VIASPAN solution 
and then re-oxygenated in Krebs-Henseleit at 37° C. As shown  in Figure 4A, chemical inhibition of 
the 3 key enzymes of carbohydrate, lipid and aminoacids catabolism, pyruvate kinase (KPYR), 3-
ketoacyl-CoA thiolase (THIM) and arginase 1 (ARGI1) by suramine (SUR, 20 mol/L), 
trimetazidine (TMZ, 100 mol/L) and norvaline (NRV, 50 mol/L) respectively, significantly 
reduced the protection given by CGS21680 against reperfusion damage. On the same line, 


































































mixture (10%) or pyruvate (10 mol/L) significantly reduced HP and LSEC mortality induced by 
60 min reoxygenation, partially reproducing the cytoprotective action of CGS21680 (5mol/L) 
supplementation (Fig.4B).  
Functional validation of the antioxidant effect of A2aR stimulation on LSEC  
Proteomic data showed that A2aR stimulation increased the expression of several antioxidant 
enzymes, that were instead reduced following IR, particularly in LSEC (Fig.1, Supplementary Table 
1,2 and 3). These observations were functionally confirmed by evaluating the susceptibility to 
oxidative stress of primary mouse HP and LSEC upon 30 min exposure to H2O2 (500 mol/L).  
H2O2 treatment significantly increased ROS and cell damage in LSEC but not in HP. The 
stimulation of A2aR with CGS21680 abolished ROS production and prevented the loss of LSEC 




Ischemia/reperfusion damage causes up to 10% of early organ graft failure following liver 
transplantation, and can lead to a higher incidence of both acute and chronic rejections. Minimizing 
the adverse effects of this injury could significantly increase the number of transplantable livers 
improving the outcome of the grafts (5-7). Ischemic preconditioning demonstrated its efficacy in 
several models (2-7) and different pharmacological preconditioning approaches have been 
developed to overcome limitations of surgical preconditioning (2-7,13). Previous studies have 
shown that pre-treatment with the A2aR agonist CGS21680 enhanced tolerance against hepatic IR 
damage (4,11). This work describes for the first time the proteome alterations of mouse HP and 
LSEC isolated from livers exposed to IR in the presence or absence of A2aR stimulation elucidating 


































































Our work has pointed out profound modifications of HP and LSEC proteome and enzymatic 
activities contributing to clarify critical processes involved in IR injury and liver preconditioning, 
implementing and dissecting the previous observations obtained in entire liver (24-29). 
Considering all identified proteins, few of the affected proteins were shared between HP and LSEC, 
highlighting the diversity of these cells and the importance to analyse them separately. However the 
pathways involved were almost the same (metabolism, stress response, protein folding and 
regeneration), showing a general common response, but with the prevalence of metabolic effects in 
HP and stress-related effects in LSEC. Notably, the profiling of the enzymatic and functional 
activities reduced by IR and rescued by CGS21680 were almost completely overlapped with those 
observed by proteomics.  
The severe ATP depletion during ischemic phase in HP has been generally ascribed to the lack of 
O2 and glycolytic substrates supply consequent to blood interruption (2-4). Such alteration is 
however prevented in preconditioned ischemic liver, indicating  that the block of blood supply is 
not per se sufficient to justify the ATP loss. In addition, one of the most striking alteration of IR 
injured liver is its incapability of recovering aerobic ATP production at blood flow reestablishment 
with reperfusion. The observation that glycolytic enzymes and ATP synthases subunits were 
decreased in HP and LSEC derived from liver exposed to IR and that CGS21680 treatment 
combined to IR up-regulated the glycolytic and mitochondrial pathways endorses the hypothesis 
that IR damage is not merely due to a reduction of blood flow requirement, but to a coordinate 
perturbation of metabolic enzymes expression, that is rescued by preconditioning.   
Furthermore, the liver acts as a major organ for lipid metabolism and that hepatic aerobic ATP 
synthesis is strictly dependent on lipid supply and catabolism. Interestingly we found that 
CGS21680 treatment is able to promote the lipid transport and  -oxidations, which were instead 
down-modulated by IR. It would be interesting in the future to evaluate the impact of  -oxidation 


































































The up-regulation of urea cycle enzymes and the increase of activity of two key enzymes of this 
pathway (CPSM and ARGI1) following CGS21680 treatment  was observed. This suggests that the 
improvement of amino acids catabolism could represent a response of HP and LSEC to ATP 
deprivation caused by IR. 
All together, these results indicated that the down-regulation of key metabolic enzymes can explain 
the ATP loss caused by IR. Therefore, A2aR stimulation provides a general metabolic advantage to 
HP and LSEC, demonstrated by ATP production increasing, not only rescuing the metabolic 
alteration induced by IR but in some cases enhancing the expression of enzymes  required for 
energy production.  
The relevance of our observations about the metabolic advantage provided by CGS21680 is also 
supported by the fact that the cytoprotective action of CGS21680 is reverted  by the inhibition of 
pyruvate kinase (KPYR), 3-ketoacyl-CoA thiolase (THIM) and arginase (ARGI1), three enzyme of 
glycolysis, -oxidation and urea cycle respectively, that are impaired by IR. Furthermore, cell 
supplementation with the glycolic end-product pyruvate, the free fatty acid palmitic acid or 
aminoacid mixture demonstrated to partly mimic the protective effects of CGS21680 against HP 
and LSEC hypoxia-reoxygenation damage. 
Notably among the 28 metabolic proteins identified, only 14 of them were already connected to IR 
and preconditioning (FABPL, ATPB, FABPI, ENOA, ATPA, ARGI1, ALDOB, ETFA, THIM, 
CPSM, TPIS, OTC, HINT, FABP5) (5, 25-27, 29-32), while the others are completely new (GLYC, 
IDHC, KPYR, DHSO, FAAA, S2542, PGK1, CLC4F, ODBA, NDKB, ATP5H, PROSC, ECH1, 
AL4A1). 
Another fundamental aspect is the role of antioxidant enzymes in the protection against IR injury by 
preconditioning. We detected several proteins involved in liver cell response to oxidative stress. 
Many of these proteins (GRP75, GSTP1, SBP2, PPIA, GSTM1, CATA, PRDX6, CH60, PDIA3) 
were already known to be involved in IR and preconditioning processes (5, 25-29).  Catalase, 


































































highly effective antioxidant present in elevated concentrations in HP (34). PRDX6 is another well-
known antioxidant demonstrated to normalize mitochondrial respiration during IR (27). Finally, the 
chaperones GRP75, PDIA1, PDIA3, CH60 can be involved in protein folding repair mechanism, 
together with the 2 proline isomerase PPIA and FKB1B, since ROS are known to cause protein 
misfolding (35). The majority of stress proteins that we have identified have mitochondrial origin, 
confirming previous observation  (29, 36).  
We observed that CGS21680 treatment generally increased the antioxidant defences particularly in 
LSEC, whereas IR depressed the antioxidant enzymes content in LSEC exclusively and that 
CGS21680 treatment of these cells prevented oxidative damage following in vitro addition of H2O2. 
These results may explain the high sensitivity of LSEC to cold ischemia and the microcirculatory 
disturbance induced by IR damage as well as the rescuing action of ischemic preconditioning (2).  
An intriguing aspect that may deserve further analysis is that the combined treatment of CGS21680 
plus IR results often more effective in producing protective protein modifications than that with 
CGS21680 alone. This suggests that the genomic changes induced by A2aR stimulation accomplish 
a full-protected phenotype only in presence of cell stress. Indeed recent results showed that A2aR 
stimulation might effectively prevent also pathological conditions different by IR through the 
activation of  noxious-specific mechanisms of protection (37).  
In conclusion, this study contributed to the understanding of the molecular bases of IR injury and 
cytoprotection by A2aR stimulation, showing specific modifications of HP and LSEC proteomes. 
The great number of new proteins identified demonstrate the strength of our experimental approach. 
Finally this study, showing the importance of glycid, lipid, aminoacids and antioxidants availability 
in IR injury and in A2aR-induced liver cell protection, suggest the protective potential of 
supplementing organ preservation solutions with energy-linked metabolites and natural or synthetic 
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FIGURE LEGENDS   
Figure 1   
Differentially expressed proteins upon IR, A2aR stimulation or A2aR stimulation plus IR.  
Down-regulated (black) and up-regulated (white) identified proteins associated or not (others) to 
metabolism (glycid, lipid, mitochondrial and aminoacid metabolism) or stress-response/folding 
processes in control conditions or upon A2aR stimulation with the A2aR agonist CGS21680 or IR 
in presence or in absence of CGS21680 treatments. All pair conditions were examined.  
Figure 2  
Graphical abstract of the main pathways involved in IR and A2aR stimulation in HP and 
LSEC. Identified proteins are indicated.  
Figure 3 
Effects of IR, A2aR stimulation or A2aR stimulation plus IR on metabolic activities. 
Enzymatic activities of (A) fructose-bisphosphate aldolase B (ALDOB), -enolase (ENOA), and 
pyruvate kinase (KPYR), of  (B) -oxidation reactions, of  (C) carbamoyl-phosphate synthase 
(CPSM) and  arginase 1 (ARGI1) and of (D)  isocitrate dehydrogenase (IDHC), cytochrome C and 
the ATP production were evaluated in HP and LSEC. The results are means ± S.D. of four 
experiments.  *p<0,01, #p≤0,05  
Figure 4  
A2aR stimulation protects HP and LSEC against hypoxia-reoxygenation injury by promoting  
glycid, lipid and aminoacids catabolism. 
Viability of primary mice HP  and LSEC conserved for 16 hours in cold hypoxic conditions and 
exposed to 60 minutes of warm reoxygenation. 
HP and LSEC were conserved in VIASPAN solution in presence or in absence of: A)  the 3-
ketoacyl-CoA thiolase inhibitor  trimetazidine (TMZ, 100 mol/L), the arginase inhibitor norvaline 


































































the A2aR agonist CGS21680 (5 mol/L) or B) palmitic acid  (2 mol/L) (PA),  non essential 
aminoacids mixture (10%) (AA),  pyruvate (10 mol/L) or CGS21680 (5 mol/L).  
The results are means ± S.D. of four experiments.  *p<0,001, #p<0,01  
Figure 5  
CGS21680 prevents oxidative species production and oxidative damage of LSEC.   
Intracellular oxidative species production evaluated as DCFH-DA intracellular fluorescence 
intensity  (A) and viability (B) of primary mice HP and LSEC after 30 min exposure to H2O2 (500 
mol/L). The results are means ± S.D. of four experiments.  *p<0,001, #p<0,01. 
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Male C57BL6  mice were anesthetized with isoflurane, the abdominal cavity was opened, the liver vessels were exposed and normothermic partial 
hepatic ischemia was induced by the clamping of portal structures to the left and median lobes with a micro vascular clip; this yielded 
approximately 70% of hepatic ischemia. The abdomen was covered with saline-humidified gauze during the ischemic period. After 30 minutes of 
partial hepatic ischemia, the clip was removed to initiate hepatic reperfusion, the abdominal cavity was closed with a 4-0 silk suture and metal clips 
were applied to the skin. The temperature was maintained at 37°C during hepatic ischemia and in the post surgical period with a warming pad. 
Sham-operated mice underwent the same procedure without clamping of the pedicle of the liver lobes. Mice were randomly assigned to 1 of 4 group 
with a sample size of 4 mice per group. CGS21680 (0.5 mg/kg) was administered by intraperitoneal injection 20 min before the ischemia procedure. 
Mice were killed 120 min after reperfusion or employed for the procedures of liver cells isolation. For the “in vivo” analysis of liver injury, before 
mice sacrifice, blood was collected for serum ALT transaminase activity determination. Tissues from ischemic lobes were fixed in 4% 
formaldehyde and then embedded into paraffin. Sections were cut and stained with hematoxylin and eosin for histological analysis.  
Liver cells isolation 
Liver cells were isolated from sham operated mice or mice exposed to hepatic ischemia/reperfusion and treated or not with the A2aR agonist 
CGS21680 (0.5 mg/kg), after liver perfusion by collagenase digestion. After liver digestion, cells were dispersed and HP recovered by differential 
centrifugation. An initial immunomagnetic separation by a mouse anti-CD45 antibody linked to immunomagnetic beads (Miltenyi biotec.) was used 
to collect hematopoietic cells.  The negative fraction of the CD45+ cells was used to isolate LSEC by positive selection with anti-CD146 antibody 
linked to immunomagnetic beads. Typically, the yield of LSEC cells was 5x106 per mouse liver and average of 40x106 HP (15). 
Cell viability estimated at the beginning of the experiments, ranged from 82% to 90%.  
Isolated HP and LSEC for proteomic analysis were stored at -80°C until solubilization.  
Measurement of Reactive Oxygen Species (ROS) 
Cells were incubated for 10 minutes at 37°C with 5 µmol/L DCFH-DA in phosphate-buffered saline. After 2 washes with phosphate-buffered saline, 
cells were transferred to a fluorometer cuvette, and the fluorescence was recorded with a Hitachi F-4500 fluorescence spectrophotometer (490-nm 
excitation and 530-nm emission). ROS production was calculated as a percentage of the DCFH-DA fluorescence intensity versus untreated control 
cells. 
Proteomic analysis 
Samples preparation  
Samples were solubilized in a solution containing 9 M urea, 4% w/v CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate), 
protease inhibitors and nuclease. The sample was incubated O.N. at 4°C and spun down at 13,800 g for 10 min at 4°C. The clear supernatant 
recovered, quantified with DC Protein assay kit and stored at -20°C until analysis. 
Two-dimensional gel electrophoresis (2-DE) coomassie-stained gels 
2-DE was performed using ready-made IPG strip (17-cm IPG strips, pH 3-10NL). Each sample (1 mg of total liver protein) was applied onto an IPG 
gel by in-gel rehydration for 20 h, adding DTT 1% w/v, final concentration and ampholine pH 3.5–10, 2% v/v, final concentration. Isoelectric 
focusing, strips equilibration and second dimension were performed as previously described (16). Gels were stained with colloidal Coomassie (18% 
v/v ethanol, 15% w/v ammonium sulfate, 2% v/v phosphoric acid, 0.2% w/v Coomassie G-250) for 48 h. 
2D DIGE 
Samples were labelled with CyDye DIGE Fluors following the manufacturer’s instruction (GE Healthcare). Fifty micrograms of each sample was 
minimally labelled with 400 pmol of either 
Cy 2 or Cy3 or Cy5. Cy3 and Cy5 were alternately used for samples, whereas Cy2 was used for the internal standard (a pooled standard containing 
total liver proteins treated or not with CGS21680). Labelling reactions were performed in the dark for 30 min on ice and then quenched with the 
addiction of 10mM lysine. Three 2D DIGE experiments (containing one gel each) were performed to analyse three biological replicates of control 
and CGS21680 or IR and CGS21680+IR samples. 2-DE was performed as described above.  
Image analysis 
Gel images were acquired with ChemiDoc Imaging System (Bio-Rad).  
Image analysis was performed using PD-Quest software (version 7.2, Bio-Rad) according to the manufacturer’s instructions. Normalization of each 
individual spot was performed according to the total quantity of the valid spots in each gel, after subtraction of the background values. The spot 
volume was used as the analysis parameter to quantify protein expression. 
Protein identification by mass spectrometry and database search 
Coomassie G-stained spots were excised from 2-DE preparative gels; destaining and in-gel enzymatic digestion performed as previously described 
(16). All digests were analyzed by MALDI-TOF (TofSpec SE, MicroMass) equipped with a delayed extraction unit. Peptides solution was prepared 
with equal volumes of saturated a-cyano-4-hydroxycinnamic acid solution in 40% v/v acetonitrile-0.1% v/v trifluoroacetic acid. The MALDI-TOF 
was calibrated with a mix of PEG (PEG 1000, 2000 and 3000 with the ratio 1:2:2) and mass spectra were acquired in the positive-ion mode. Peak 
lists were generated with ProteinLynx Data Preparation (ProteinLynx Global Server 2.2.5) using the following parameters: external calibration with 
lock mass using mass 2465.1989 Da of ACTH, background subtract type adaptive combining all scans, performing deisotoping with a threshold of 
1%. The 25 most intense masses were used for database searches against the SWISSPROT database using the free search program MASCOT 
(http://www.matrixscience.com). The following parameters were used in the searches: taxa Mus musculus, trypsin digest, one missed cleavage by 
trypsin, carbamidomethylation of cysteine as fixed modification, methionine oxidation as variable modifications and maximum error allowed 100 
ppm. Were taken on to consideration only protein with a Mascot score≥56. 
Western blotting 
Lysates containing equal amounts of proteins (30 µg),  containing Laemmli buffer,  were subjected to SDS/PAGE (12% gel). The separated proteins 
were transferred to a nitrocellulose membrane. The blot was blocked using 5% w⁄ v dried no fatty milk in PBS containing 0.1% Tween-20, and 
probed using rabbit antibody against arginase 1 (diluted 1:1000), mouse antibody against α-enolase (diluted 1:5000), rabbit antibody against 3-
ketoacyl-CoA thiolase (diluted 1:3000) overnight at 4°C. After washing using PBS containing 0.1% Tween-20 for 30 min, the blot was incubated 
for 1 h with horseradish-peroxidase labeled antibodies against rabbit or mouse IgG (diluted 1:10000), and immunoreactivity was detected using an 
enhanced chemiluminescence kit. 
Real-time quantitative RT-PCR 
Total RNA was  isolated from frozen isolated HP and LSEC taken from sham liver or liver exposed to ischemia-reperfusion from mice treated or 
not with CGS21680, using the ChargeSwitch® Total RNA Cell Kit (Applied Biosystems Italia, Monza, Italy) following manufacturer’s instructions. 
RNA was reverse transcribed for first-strand complementary DNA (cDNA) synthesis using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems Italia, Monza, Italy) according to the manufacturer’s recommendations. Quantitative real-time polymerase chain reaction (RT-
PCR) was performed in the CFX96 Touch™ Real-Time PCR Detection System-Bio-Rad (Bio-Rad Laboratories S.r.l, Milan, Italy) using TaqMan 
Gene Expression Master Mix and Taqman Gene Expression probes for mouse 3-ketoacyl-CoA thiolase (THIM), arginase1 (ARGI1), α-enolase 
(ENOA), and β-actin or 18S as control genes (Applied Biosystems Italia, Monza, Italy). All samples were ran in duplicate, and the relative gene 
expression calculated as 2-ΔCt is expressed as fold increase over control samples. Values were normalized to those of β-actin for ENOA or to those of 
18S for THIM and ARGI1 and expressed by using the comparative 2-ΔCt method. 
Enzymatic assays 
Glycid metabolism 
Cells were rinsed with PBS, sonicated with 10 bursts of 1 s, centrifuged at 13,000 x g for 5 min, re-suspended in 100 mmol/L Tris (pH 7.4). A 50 
µL aliquot was used for the protein quantification with the BCA Kit (Sigma Chemical Co., St. Louis, MO). 50 µg of whole cell lysates were used in 
each assay.  
Aldolase B activity was measured as described in (17), with minor modifications: samples were incubated at 37°C, in the presence of 100 mmol/L 
K2HPO4 (pH 7.2), 1 mmol/L fructose 1,6-biphosphate, 10 mmol/L EDTA, 2 mg/mL α-glycerophosphate dehydrogenase, 2 mg/mL triose phosphate 
isomerase, 100 µg/mL bovine serum albumin, 0.15 mmol/L NADH, in a final volume of 300 µL. The rate of NADH oxidation was followed for 5 
min, monitoring the absorbance at 340 nm with a Packard microplate reader EL340 (Bio-Tek Instruments, Winooski, VT). Results were expressed 
as nmol NADH produced/min/mg cell proteins. Enolase A activity was measured accordingly to (18). Results were expressed as nmol 
NAD+/min/mg cell proteins.  
The activity of pyruvate kinase was detected with the Enzymatic Assay of Pyruvate Kinase kit, following the manufacturer’s instruction. Results 
were expressed as nmol NAD+/min/mg cell proteins. 
Lipid metabolism 
Fatty acids β-oxidation was measured as previously reported (19), with minor modifications. Cells were washed twice with PBS, detached with 
trypsin/EDTA (0.05/0.02% v/v) and centrifuged at 13,000 x g for 5 min. A 50 µL aliquot was collected, sonicated and used for the intracellular 
protein quantification. The remaining sample was re-suspendend in culture medium containing 0.24 mmol/L fatty acid-free bovine serum albumin, 
0.5 mmol/L L-carnitine, 20 mmol/L Hepes, 2 µCi [1-14C]palmitic acid (3.3 mCi/mmol) and transferred into test tubes tightly sealed with rubber 
caps. After 2 h incubation at 37°C, 0.3 mL of a 1:1 v/v phenylethylamine/methanol solution was added into each sample by a syringe, followed by 
0.3 mL of 0.8 N HClO4. Samples were incubated for 1 h further at room temperature, then centrifuged at 13,000 x g for 10 min. Both supernatants, 
containing 14CO2, and precipitates, containing 14C-acid soluble metabolites (ASM), were collected. The radioactivity of each sample was counted by 
liquid scintillation. Results were expressed as pmol of [14CO2] or 14C-ASM/h/mg cell proteins. 
Aminoacid metabolism 
The activity of carbamoyl phosphate synthetase I was measured on mitochondrial extracts, isolated as reported previously (20). Samples were 
sonicated and a 50 µL aliquot was used for protein quantification . 25 µg of mitochondrial proteins were incubated in 0.5 mL of the assay buffer (87 
mmol/L Tris/HCl, 87 mmol/L KCl, 25 mmol/l MgCl2, 10 mmol/L ATP, 20 mmol/L NH4Cl, 0.8 mmol/L dithiothreitol, 6.5% v/v dimethyl sulfoxide, 
2.2% v/v glycerol) with 4 µCi [14C]-NaHCO3 (54 mCi/mmol) for 30 minutes at 37°C. The reaction was stopped by adding 0.2 mL of 80% w/v 
trichloroacetic acid. To remove the unincorporated 14CO2, the tubes were heated at 85°C for 3 h; the remaining samples, containing [14C]-carbamoyl 
phosphate, were analyzed by liquid scintillation counting. Results were expressed as pmol carbamoyl phosphate/min/mg cell proteins.  
Arginase activity was measured on 50 µg of whole cell lysates by a spectrophotometric method (21). Results were expressed as µmol urea/mg cell 
proteins. 
Mitochondrial metabolism 
Mitochondria were isolated as reported above. 
To measure the isocitrate dehydrogenase activity, 25 µg mitochondrial proteins were re-suspended in 0.3 mL of Tris-acetate (pH 7.4), containing 5 
mmol/L DL-isocitrate trisodium salt and 5 mmol/L MgCl2. The reaction was started by adding 0.5 mmol/L NAD+ and the absorbance at 340 nm 
was followed for 5 minute. Results were expressed as nmol NADH/mg mitochondrial proteins. 
The rate of cytochrome c reduction was taken as an index of the activity of the electron flux from complex I to complex III, and was measured 
according to (22) with minor modifications. 50 µg of non-sonicated mitochondrial samples, re-suspended in 0.59 mL buffer A (5 mmol/L KH2PO4, 
5 mmol/L MgCl2, 5% w/v bovine serum albumin), were transferred into a quartz spectrophotometer cuvette. Then 0.38 mL buffer B (25% w/v 
saponin, 50 mmol/L KH2PO4, 5 mmol/L MgCl2, 5% w/v bovin serum albumin, 0.12 mmol/L cytochrome c-oxidized form, 0.2 mmol/L NaN3) were 
added for 5 min at room temperature. The reaction was started with 0.15 mmol/L NADH and was followed for 5 min, reading the absorbance at 550 
nm by a Lambda 3 spectrophotometer (PerkinElmer).  
The ATP level in mitochondria extracts was measured with the ATP Bioluminescent Assay Kit, using a Synergy HT Multi-Mode Microplate Reader 
(Bio-Tek Instruments). ATP was quantified as arbitrary light units and converted into nmol ATP/mitochondrial proteins, according to the calibration 










ABHEB (Abhydrolase domain-containing protein 14B); ALDH2 (Aldehyde dehydrogenase, mitochondrial); AL4A1 (Delta-1-pyrroline-5-
carboxylate dehydrogenase, mitochondrial); ALDOB (Fructose-bisphosphate aldolase B); ATPA (ATP syntase A), ATPB (ATP syntase B); 
ATP5H (ATP synthase subunit d, mitochondrial); ARGI1 (Arginase-1); ASXL3 (Putative Polycomb group protein ASXL3); CAH3 (Carbonic 
anhydrase 3); CALM (Calmodulin); CATA (Catalase); CATB (Cathepsin B); CH60 (60 kDa heat shock protein, mitochondrial); CHD1 
(Chromodomain-helicase-DNA-binding protein 1); CJ088 (Uncharacterized protein C10orf88 homolog); CK054 (Ester hydrolase C11orf54 
homolog); CLC4F (C-type lectin domain family 4 member F); CPSM (Carbamoyl-phosphate synthase [ammonia], mitochondrial); DHSO 
(Sorbitol dehydrogenase); DNM3A (DNA (cytosine-5)-methyltransferase 3); ECH1 (Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial); 
EF1B (Elongation factor 1-beta); EF2 (Elongation factor 2); ENOA (Alpha-enolase); ETFA (Electron transfer flavoprotein subunit alpha, 
mitochondrial); FAAA (Fumarylacetoacetase); FABP5 (Fatty acid-binding protein, epidermal); FABPI (Fatty acid-binding protein, intestinal); 
FABPL (Fatty acid-binding protein, liver); FKB1B (Peptidyl-prolyl cis-trans isomerase FKBP1B); GLYC (Serine hydroxymethyltransferase, 
cytosolic); GRP75 (Stress-70 protein, mitochondrial); GSTM1 (Glutathione S-transferase Mu 1); GSTP1 (Glutathione S-transferase P 1); GSTP2 
(Glutathione S-transferase P 2); 3HAO (3-hydroxyanthranilate 3,4-dioxygenase); HINT1 (Histidine triad nucleotide-binding protein 1); IDHC 
(Isocitrate dehydrogenase [NADP] cytoplasmic); IPYR (Inorganic pyrophosphatase); K2C8 (Keratin, type II cytoskeletal 8); KPYR (Pyruvate 
kinase isozymes R); MCM2 (DNA replication licensing factor MCM2); MIC1 (Uncharacterized protein C18orf8 homolog); MUP8 (Major urinary 
proteins 8 (Fragment)); NDKB (Nucleoside diphosphate kinase B); ODBA (2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial); OTC 
(Ornithine carbamoyltransferase, mitochondrial); PDIA1 (Protein disulfide-isomerase); PDIA3 (Protein disulfide-isomerase A3); PEBP1 
(Phosphatidylethanolamine-binding protein 1); PGK1 (Phosphoglycerate kinase 1); PPIA (Peptidyl-prolyl cis-trans isomerase A); PRDX6 
(Peroxiredoxin-6); PROSC (Proline synthase co-transcribed bacterial homolog protein); RGN (Regucalcin); ROA2 (Heterogeneous nuclear 
ribonucleoproteins A2); S2542 (Solute carrier family 25 member 42); SBP2 (Selenium-binding protein 2); SNX5 (Sorting nexin-5); THIM (3-






Table 1. IR modulated spots Spot number (SSP), accession number on SwissProt database (AC), name, densitometric ratio between IR and control 
sample, p value, biological function, number of matched mass values (match. pept.) on number of total mass values searched (25), coverage 
percentage and Mascot score are indicated. 
 
 





25 coverage % 
Mascot 
score 
HP 1506 EF1B O70251 Elongation factor 1-beta 0,11 0,002 
protein 
biosynthesis 5 24 56 
 2503 Mixture   0,34 0,038    108 




biosynthesis 8 31 88 
  KPYR P53657 Pyruvate kinase isozymes R/L   
metabolism, 
glycolysis 7 18 60 
 2602 ATPB Q3U774 
ATP synthase subunit beta, 
mitochondrial 0,25 0,009 
metabolism, 
oxidative 
phosphorylation 15 44 192 
 4303 FABPI P55050 Fatty acid-binding protein, intestinal 0,32 0,013 
metabolism, 
lipid binding 
protein 8 54 106 
 4703 ENOA P17182 Alpha-enolase 0,21 0,032 
metabolism, 
glycolysis 9 36 116 
 6402 ATPA Q03265 
ATP synthase subunit alpha, 
mitochondrial 0,39 0,015 
metabolism, 
oxidative 
phosphorylation 8 21 61 
LSEC 701 PDIA1 P09103 Protein disulfide-isomerase 0,18 0,054 stress protein 12 28 126 
 1604 ATPB Q3U774 
ATP synthase subunit beta, 
mitochondrial 0,14 0,029 
metabolism, 
oxidative 
phosphorylation 16 45 222 
 3505 CLC4F P70194 C-type lectin domain family 4 member F 0,20 0,039 
metabolism, 
receptor with an 
affinity for 
galactose and 
fucose 7 15 56 
 5512 CATA P24270 Catalase 0,05 0,040 stress protein 9 24 93 
 5515 ODBA P50136 2-oxoisovalerate dehydrogenase subunit 0,26 0,015 metabolism, 13 38 138 
alpha, mitochondrial conversion of 
alpha-keto 
acids to acyl-
CoA and CO2 
 5908 CJ088 Q9D2Q3 
Uncharacterized protein C10orf88 
homolog 0,12 0,016 unknown 6 18 57 





other than ATP 11 69 132 
 8409 ROA2 O88569 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 0,25 0,052 
pre-mRNA 























Table 2. CGS modulated spots Spot number (SSP), accession number on SwissProt database (AC), name, densitometric ratio between CGS and 
control sample, p value, biological function number of matched mass values (match. pept.) on number of total mass values searched (25), coverage 




 SSP  AC name CGS/control p value function 
match. pept./ 
25 coverage % 
Mascot 
score 
HP 1604 IPYR Q9D819 Inorganic pyrophosphatase 3,22 0,018 pyrophosphatase 10 42 122 
 4901 GLYC P50431 
Serine 
hydroxymethyltransferase, 
cytosolic 0,48 0,025 
metabolism, 
aminoacids 9 25 87 
 5609 IDHC O88844 
Isocitrate dehydrogenase 
[NADP] cytoplasmic 4,74 0,009 
metabolism, 
Krebs cycle 7 25 64 
 9949 FABPL P12710 
Fatty acid-binding protein, 
liver 5,58 0,031 
metabolism, 
lipids binding 
protein 6 61 82 
LSEC 3410 Mixture   4,41 0,001    75 
  OTC P11725 
Ornithine 
carbamoyltransferase, 
mitochondrial   
metabolism, urea 
cycle 6 22 59 
  PGK1 P09411 Phosphoglycerate kinase 1   
metabolism, 
glycolisis 6 26 57 
 5602 ENOA P17182 Alpha-enolase 1,67 0,051 
metabolism, 
glycolisis 13 44 154 
 8604 THIM Q8BWT1 
3-ketoacyl-CoA thiolase, 
mitochondrial 2,84 0,052 
metabolism, fatty 
acids beta 











Table 3. CGS+IR modulated spots Spot number (SSP), accession number on SwissProt database (AC), name, densitometric ratio between 
CGS+IR and control, CGS or IR sample, p value, biological function, number of matched mass values (match. pept.) on number of total mass values 
searched (25), coverage percentage and Mascot score are indicated. 
 
 SSP  AC name 
CGS+IR/ 
control p value function 
match. pept./ 
25 coverage % 
Mascot 
score 
HP 804 GRP75 P38647 
Stress-70 protein, 
mitochondrial 0,47 0,042 stress protein 7 14 61 
 2202 FABPI P55050 
Fatty acid-binding 
protein, intestinal 5,51 0,039 
metabolism, lipids 
binding protein 8 54 106 
 2203 ABHEB Q8VCR7 
Abhydrolase 
domain-containing 
protein 14B 4,19 0,051 
hydrolase activity 
towards p-nitrophenyl 
butyrate 5 37 64 
 4202 GSTP1 P19157 
Glutathione S-
transferase P 1 0,46 0,007 stress protein 7 40 84 
 4803 ARGI1 Q61176 Arginase-1 2,99 0,029 
metabolism, urea 
cycle 10 40 105 
 8201 MCM2 P97310 
DNA replication 
licensing factor 
MCM2 13,09 0,020 DNA replication 10 12 62 
 9105 FABPL P12710 
Fatty acid-binding 
protein, liver 0,26 0,030 
metabolism, lipids 
binding protein 7 60 78 
LSEC 3301 ATP5H Q9DCX2 
ATP synthase 
subunit d, 
mitochondrial 5,79 0,029 
metabolism, oxidative 
phosphorylation 5 39 58 
 4401 OTC P11725 
Ornithine 
carbamoyltransferas
e, mitochondrial 22,01 0,012 
metabolism, urea 
cycle 6 19 57 
 4605 Mixture   6,20 0,014    75 
  OTC P11725 
Ornithine 
carbamoyltransferas
e, mitochondrial   
metabolism, urea 
cycle 6 22 59 
  PGK1 P09411 
Phosphoglycerate 
kinase 1   
metabolism, 
glycolisis 6 26 57 
 4702 CATA P24270 Catalase 15,27 0,019 stress protein 9 24 93 
 6210 FABPL P12710 
Fatty acid-binding 
protein, liver 7,38 0,049 
metabolism, lipids 
binding protein 7 51 60 
 6212 ASXL3 Q8C4A5 
Putative Polycomb 
group protein 
ASXL3 110,23 0,002 transcriptional control 12 8 56 
 7702 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 3,15 0,044 
metabolism, fatty 
acids beta oxidation 8 28 82 
 SSP  AC name 
CGS+IR/ 
CGS p value function 
match. pept./ 
25 coverage % 
Mascot 
score 
HP 1502 K2C8 P11679 
Keratin, type II 
cytoskeletal 8 0,27 0,035 structural 11 24 106 
 2504 Mixture   3,70 0,042    108 
  RGN Q64374 Regucalcin   
calcium binding 
protein; vitamine C 
biosynthesis 8 31 88 
  KPYR P53657 
Pyruvate kinase 
isozymes R/L   
metabolism, 
glycolysis 7 18 60 
 3502 IPYR Q9D819 
Inorganic 
pyrophosphatase 0,35 0,027 pyrophosphatase 10 42 122 
 3601 ENOA P17182 Alpha-enolase 2,47 0,033 
metabolism, 
glycolysis 9 27 92 
 3702 SBP2 Q63836 
Selenium-binding 
protein 2 3,69 0,018 stress protein 10 33 121 
 3705 SBP2 Q63836 
Selenium-binding 
protein 2 2,77 0,029 stress protein 11 29 134 
 3708 GRP75 P38647 
Stress-70 protein, 
mitochondrial 5,09 0,010 
stress, folding of 
proteins 9 16 82 
 4401 3HAO Q78JT3 
3-
hydroxyanthranilate 
3,4-dioxygenase 2,98 0,045 cofactor biosynthesis 6 31 61 
 4501 ARGI1 Q61176 Arginase-1 3,59 0,004 
metabolism, urea 
cycle 9 40 103 
 4706 ENOA P17182 Alpha-enolase 0,25 0,021 
metabolism, 
glycolysis 9 36 116 
 4707 ALDH2 P47738 
Aldehyde 
dehydrogenase, 
mitochondrial 4,52 0,011 stress protein 14 33 181 
 5203 PPIA P17742 
Peptidyl-prolyl cis-
trans isomerase A 3,25 0,027 folding of proteins 5 24 74 
 5302 GSTM1 P10649 
Glutathione S-
transferase Mu 1 3,63 0,043 
stress, folding of 
proteins 7 39 75 
 5502 ARGI1 Q61176 Arginase-1 6,34 0,055 
metabolism, urea 
cycle 10 36 112 
 5504 DHSO Q64442 
Sorbitol 
dehydrogenase 3,08 0,026 
metabolism, sorbitol 
to fructose conversion 7 32 71 
 5505 Mixture   4,89 0,004    106 
  DHSO Q64442 
Sorbitol 
dehydrogenase   
metabolism, sorbitol 
to fructose conversion 8 36 86 
  ARGI1 Q61176 Arginase-1   
metabolism, urea 
cycle 6 25 58 
 5506 ARGI1 Q61176 Arginase-1 5,21 0,015 
metabolism, urea 






aldolase B 3,59 0,026 
metabolism, 
glycolysis 6 20 56 
 5603 FAAA P35505 Fumarylacetoacetase 3,81 0,051 
metabolism, aa 
degradation 10 39 108 
 5701 ENOA P17182 Alpha-enolase 2,37 0,050 
metabolism, 
glycolysis 13 44 154 
 6203 MIC1 Q8VC42 
Uncharacterized 
protein C18orf8 
homolog 2,52 0,021 unknown 7 20 70 
 6302 ATPA Q03265 
ATP synthase 
subunit alpha, 
mitochondrial 1,85 0,029 
metabolism, oxidative 
phosphorylation 8 21 61 
 6402 ETFA Q99LC5 
Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 4,14 0,038 
metabolism, oxidative 
phosphorylation 8 39 92 
 7401 CAH3 P16015 
Carbonic anhydrase 
3 2,58 0,036 
reversible hydration 
of carbon dioxide 12 51 168 
 9402 VDAC1 Q60932 
Voltage-dependent 
anion-selective 
channel protein 1 2,41 0,042 
cell volume 
regulation and 
apoptosis 7 44 89 
 9601 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 3,37 0,020 
metabolism, fatty 






3A 27,48 0,043 DNA methylation 9 11 66 
 2201 PROSC Q9Z2Y8 
Proline synthase co-
transcribed bacterial 
homolog protein 8,96 0,013 
metabolism, 
aminoacids 5 20 57 
 2203 MUP8 P04938 
Major urinary 
proteins 11 and 8 
(Fragment) 2,71 0,053 pheromones binding 10 78 130 





 3201 ATP5H Q9DCX2 
ATP synthase 
subunit d, 
mitochondrial 0,48 0,036 
metabolism, oxidative 
phosphorylation 5 39 58 
 3304 PRDX6 O08709 Peroxiredoxin-6 92,13 0,002 stress protein 8 32 98 
 3601 ATPB Q3U774 
ATP synthase 
subunit beta, 
mitochondrial 9,79 0,003 
metabolism, oxidative 
phosphorylation 15 44 184 
 3701 CH60 P63038 
60 kDa heat shock 
protein, 
mitochondrial 0,32 0,021 stress protein 10 32 98 
 5304 PRDX6 O08709 Peroxiredoxin-6 11,16 0,010 stress protein 8 51 111 
 5401 PDIA3 P27773 
Protein disulfide-
isomerase A3 4,37 0,021 stress protein 12 25 129 
 5501 Mixture   5,04 0,010    213 














quinolinate 11 52 131 




mitochondrial   
metabolism, fatty 
acids beta oxidation 11 48 114 
 6302 EF2 P58252 Elongation factor 2 18,04 0,006 protein synthesis 14 18 115 




mitochondrial 15,04 0,001 
metabolism, urea 
cycle 11 9 64 
 7606 FAAA P35505 Fumarylacetoacetase 0,10 0,012 
metabolism, 
aminoacids 
degradation 6 24 69 
 9105 GSTP2 P46425 
Glutathione S-
transferase P 2 16,76 0,052 stress protein 5 39 60 






 9702 Mixture   0,33 0,056    84 
  CHD1 P40201 
Chromodomain-
helicase-DNA-
binding protein 1   DNA replication 12 9 70 
  ATPA Q03265 
ATP synthase 
subunit alpha, 
mitochondrial   
metabolism, oxidative 
phosphorylation 8 18 61 
 SSP  AC name 
CGS+IR/ 
IR p value function 
match. pept./ 
25 coverage % 
Mascot 
score 
HP 202 CALM Q498A3 Calmodulin 2,51 0,020 
control of a large 
number of enzymes, 
ion channels and 
other proteins by Ca2+ 5 50 57 
 3701 SBP2 Q63836 
Selenium-binding 
protein 2 2,82 0,017 stress protein 10 30 114 
 3705 SBP2 Q63836 
Selenium-binding 
protein 2 3,55 0,040 stress protein 11 29 134 
 4501 ARGI1 Q61176 Arginase-1 2,21 0,022 
metabolism, urea 
cycle 9 40 103 
 5504 DHSO Q64442 
Sorbitol 
dehydrogenase 2,44 0,044 
metabolism, sorbitol 
to fructose conversion 7 32 71 
 5505 Mixture   2,36 0,021    106 
  DHSO Q64442 
Sorbitol 
dehydrogenase   
metabolism, sorbitol 
to fructose conversion 8 36 86 
  ARGI1 Q61176 Arginase-1   
metabolism, urea 
cycle 6 25 58 
 5506 ARGI1 Q61176 Arginase-1 2,62 0,036 
metabolism, urea 
cycle 10 40 105 
 5602 GLYC P50431 
Serine 
hydroxymethyltransf
erase, cytosolic 2,35 0,013 
metabolism, 
aminoacids 9 25 87 
 5603 FAAA P35505 Fumarylacetoacetase 2,99 0,051 
metabolism, 
aminoacids 
degradation 10 39 108 
 5701 ENOA P17182 Alpha-enolase 2,95 0,037 
metabolism, 
glycolysis 13 44 154 
 6401 CPSM Q8C196 
Carbamoyl-
phosphate synthase 3,04 0,002 
metabolism, urea 
cycle 10 8 65 
[ammonia], 
mitochondrial 
 7301 Mixture   2,94 0,045    98 
  TPIS P17751 
Triosephosphate 
isomerase   
metabolism, 
glycolysis 7 28 77 
           
  S2542 Q8R0Y8 
Solute carrier family 
25 member 42   
metabolism, transport 
of coenzyme A (CoA) 
in mitochondria 7 23 56 
 7604 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 3,46 0,041 
metabolism, fatty 
acids beta oxidation 8 28 82 
 8302 GSTP1 P19157 
Glutathione S-
transferase P 1 2,88 0,031 stress protein 5 37 61 
 8602 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 3,84 0,033 
metabolism, fatty 
acids beta oxidation 13 51 166 
 8605 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 5,35 0,045 
metabolism, fatty 
acids beta oxidation 14 39 173 
 8607 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 5,34 0,030 
metabolism, fatty 
acids beta oxidation 8 28 82 
 9502 FKB1B Q9Z2I2 
Peptidyl-prolyl cis-
trans isomerase 
FKBP1B 3,30 0,004 folding of proteins 5 38 66 
 9601 THIM Q8BWT1 
3-ketoacyl-CoA 
thiolase, 
mitochondrial 2,51 0,034 
metabolism, fatty 
acids beta oxidation 11 34 124 
LSEC 1303 SNX5 Q9D8U8 Sorting nexin-5 27,99 0,028 
intracellular 
trafficking 6 24 57 
 1405 CATB P10605 Cathepsin B 10,43 0,004 
intracellular 
degradation and 
turnover of proteins 6 23 66 
 2909 GRP75 P38647 
Stress-70 protein, 
mitochondrial 6,15 0,040 stress protein 9 17 72 
 2912 GRP75 P38647 
Stress-70 protein, 
mitochondrial 11,47 0,017 stress protein 8 15 57 
 3101 FABP5 Q05816 
Fatty acid-binding 
protein, epidermal 4,13 0,002 
metabolism, lipids 
binding protein 5 31 59 
 3303 PRDX6 O08709 Peroxiredoxin-6 8,23 0,052 stress protein 8 51 111 
 3404 CK054 Q91V76 
Ester hydrolase 
C11orf54 homolog 7,03 0,003 
ester hydrolase 
activity on the 
substrate p-
nitrophenyl acetate 8 30 104 
 4103 HINT1 P70349 
Histidine triad 
nucleotide-binding 




with a single 
phosphate group 7 71 97 
 5301 ETFA Q99LC5 
Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 3,69 0,035 
metabolism, oxidative 
phosphorylation 6 31 63 
 5502 ARGI1 Q61176 Arginase-1 5,69 0,020 
metabolism, urea 
cycle 11 49 136 
 7104 PPIA P17742 
Peptidyl-prolyl cis-
trans isomerase A 3,52 0,052 folding of proteins 5 34 59 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
